VHFMoDRAD in numbers
VHFMoDRAD is a four-year European project (Collaborative Research Project) and is part of IMI’s EBOLA+ programme that was launched in 2014 to respond to the Ebola epidemic by accelerating all aspects of vaccine development and diagnostics. The project has started in January 2019 and is coordinated by Folkhälsomyndigheten (the Public Health Agency of Sweden, FoHM) represented by Professor Ali Mirazimi. The consortium brings together:
- 1) operational capacity with appropriate facilities,
- 2) experienced researchers,
- 3) authorities and entities,
- 4) clinical samples from endemic countries,
- 5) access to diagnostic hubs in epidemic areas,
- 6) a strong industrial partner, CEPHEID
- 7) SMEs and
- 8) an international network.
The project is supported by the EU’s research and innovation programme and CEPHEID Europe SAS through the Innovative Medicines Initiative (IMI). Two companies and consortium partners, Coris Bioconcept and RD Biotech, also provide financial support to the project.
6 EU, 1 Associated and 1 non EU Countries
VHFMoDRAD brings together cutting-edge complementary partners, including 1 large company, 2 small and medium enterprises, one technology transfer / management company, 9 research institution, from 6 European Member States (Sweden, UK, France, Belgium, Denmark, Italy), one NGO, one Associated country (Turkey) and an African country (Senegal), who will address the challenges of development and implementation of diagnostic tools in Africa, thus reinforcing the international and national response in the face of an outbreak.